(Note: This criterion is not considered to be met for those individuals taking opioids solely under appropriate medical supervision.) Specify if: ○ In early remission (three months of no criteria being met (with the exception of cravings) or sustained remission (12 months or longer (with the exception of cravings). ○ On maintenance therapy. ○ In a controlled environment (where access to opioids is restricted). See the DSM-5 manual for details on specifications. Specify current severity: ○ 305.50 (F11.10) Mild: Presence of 2–3 symptoms. ○ 304.00 (F11.20) Moderate: Presence of 4–5 symptoms. ○ 304.00 (F11.20) Severe: Presence of 6 or more symptoms. Symptoms of opioid intoxication depend on how much of the drug is taken and may include the following: ○ Altered mental status, such as confusion, delirium or decreased awareness or responsiveness. ○ Breathing problems (breathing may slow and eventually stop). ○ Extreme sleepiness or loss of alertness. ○ Nausea and vomiting. ○ Constipation. ○ Small pupil. (Heller, 2017) Symptoms of opioid withdrawal: ○ Early symptoms of withdrawal include: ▪ Muscle aches.
The American Psychiatric Association provides the following information in the Diagnostic Manual of Mental Disorders, 5th Edition ( DSM-5 ) (APA, 2013): DSM-5 Criteria for Opioid Use Disorder Description The following are the DSM-5 diagnostic criteria for opioid use disorder: 1. A problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period: ○ Opioids are often taken in larger amounts or over a longer period than was intended. ○ There is a persistent desire or unsuccessful efforts to cut down or control opioid use. ○ A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its effects. ○ Craving, or a strong desire or urge to use opioids. ○ Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school or home. ○ Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids. ○ Important social, occupational or recreational activities are given up or reduced because of opioid use. ○ Recurrent opioid use in situations in which it is physically hazardous. ○ Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. ○ Tolerance, as defined by either of the following: ▪ A need for markedly increased amounts of opioids to achieve intoxication or desired effect. ▪ A markedly diminished effect with continued use of the same amount of an opioid. (Note: This criterion is not considered to be met for those taking opioids solely under appropriate medical supervision.) ○ Withdrawal, as manifested by either of the following: ▪ The characteristic opioid withdrawal syndrome (refer to Criteria A and B of the criteria set for opioid withdrawal). ▪ Opioids (or a closely related substance) are taken to relieve or avoid withdrawal symptoms. Medication to treat opioid use disorder The following medications are used to treat opioid use disorder according to the Substance Abuse and Mental Health Services Administration (SAMHSA, 2016). Medication for opioid use disorders Medication-assisted treatment with methadone, buprenorphine or extended-release injectable naltrexone plays a critical role in the treatment of opioid use disorders. Opioid agonist therapies with methadone or buprenorphine reduce the effects of opioid withdrawal and reduce cravings. They have been shown to increase retention in treatment and reduce risk behaviors that lead to transmission of HIV and viral hepatitis, such as using opioids by injection. Medication-assisted treatment with extended-release injectable naltrexone reduces the risk of relapse to opioid use and helps control cravings. Extended-release injectable naltrexone is particularly useful for people exiting a controlled setting where abstinence has been enforced such as jail or residential rehabilitation or in situations where maintenance with an opioid agonist is not available or appropriate. People who misuse prescription opioids benefit
▪ Agitation, anxiety. ▪ Increased tearing. ▪ Insomnia. ▪ Runny nose.
▪ Sweating. ▪ Yawning. ○ Late symptoms of withdrawal include: ▪ Abdominal cramping, diarrhea.
▪ Dilated pupils. ▪ Goose bumps. ▪ Nausea, vomiting. (Heller, 2016)
from medication-assisted treatment as much as people abusing heroin. There are no other FDA-approved medications for the treatment of other substance use disorders. The New England Journal of Medicine (NEJM) provides an overview of current pharmacological treatment for opioid related conditions which is summarized as follows (Schuckit, 2016): Treatment of acute withdrawal syndromes – medically supervised withdrawal or detoxification – can improve the patient’s health and facilitate his or her participation in a rehabilitation program. However, by itself, medically supervised withdrawal is usually not sufficient to produce long-term recovery, and it may increase the risk of overdose among patients who have lost their tolerance to opioids (i.e., the need for higher doses of the drug to produce effects) and resume the use of these drugs. The abrupt discontinuation of opioids after long-term, intense use produces symptoms that result from physiologic
Page 69
Book Code: MIL1224
EliteLearning.com/Massage-Therapy
Powered by FlippingBook